Vitruvias Therapeutics, an Auburn, AL-based finished-dose generic drug company, has entered into a collaborative development agreement with a Hong Kong-based pharmaceutical company, Bright Future Pharmaceutical Lab to develop a portfolio of semi-solids to be marketed in the U.S. and China. U.S. distribution will be handled by Vitruvias and Bright Future will be responsible for China and other agreed upon Asian territories. The products will be manufactured by Bright Future’s newly constructed unit at its Hong Kong site specifically designed for producing products in regulated markets.
 
 “We are elated to have found a partner with the resources, rich history of success in the complex Chinese markets, and philosophical belief system that matches our own,” said Carl Whatley, chief executive officer, Vitruvias. “Bright Future has proven themselves to be an entrepreneurially-driven company with regards to their desire to become a global player in the world of dermatology, and we are very fortunate to have found such a partner.”
 
With their product development expertise, manufacturing sophistication and the ability to reach both large and small markets in China, Bright Future’s dermatology portfolio is currently the most widely prescribed brand by Chinese dermatologists.
 
The founder and chairman of the Bright Future Group, Chan Chak Yeung, said, “We are looking forward to working with the Vitruvias team to achieve our mutual goals. Their experience in the U.S. will help us implement our next objective of attaining an international presence in the field of dermatology. We also hope to work with Vitruvias to leverage our strengths in the production of other dosage forms as we pursue a broader collaboration.”